Susquehanna International Group’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Susquehanna International Group’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-71	Closed	-$5.59K	–	13762
2023 Q4	$5.59K	Buy	+71	New	+$10.6K	﹤0.01%	12122

Other funds holding VRPX

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SRCM

Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Susquehanna International Group's VRPX Position: Q1 2024 in Review

Susquehanna International Group sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 71 shares — an estimated $5.59K sold.

Susquehanna International Group first reported a position in VRPX in Q4 2023 and held it in 1 quarter. The position peaked at $5.59K in Q4 2023. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

Susquehanna International Group reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Susquehanna International Group sold 71 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $5.59K.
Susquehanna International Group first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Susquehanna International Group's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $5.59K in Q4 2023.
3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.